Cargando…

The cost-effectiveness of medication, laser trabeculoplasty, and trabeculectomy for treatment of open-angle glaucoma in South Korea

OBJECTIVES: Open-angle glaucoma (OAG) imposes high disease burden in South Korea. Although various effective interventions are available to manage the progression of OAG, there is limited data on the cost-effectiveness of these treatment strategies in South Korea. METHODS: Using a Markov cohort mode...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Jin A., Song, Lina D., Choi, Seulggie, Park, Sang Min, Kwon, Jin Woo, Jee, Donghyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336655/
https://www.ncbi.nlm.nih.gov/pubmed/30633194
http://dx.doi.org/10.1097/MD.0000000000014026
_version_ 1783388088281595904
author Choi, Jin A.
Song, Lina D.
Choi, Seulggie
Park, Sang Min
Kwon, Jin Woo
Jee, Donghyun
author_facet Choi, Jin A.
Song, Lina D.
Choi, Seulggie
Park, Sang Min
Kwon, Jin Woo
Jee, Donghyun
author_sort Choi, Jin A.
collection PubMed
description OBJECTIVES: Open-angle glaucoma (OAG) imposes high disease burden in South Korea. Although various effective interventions are available to manage the progression of OAG, there is limited data on the cost-effectiveness of these treatment strategies in South Korea. METHODS: Using a Markov cohort model, we evaluated the cost-effectiveness of 3 major treatment strategies (medication, laser trabeculoplasty, and trabeculectomy) for South Korean patients with OAG. We projected a 25-year time horizon to study a hypothetical cohort of 10,000 patients of age 40 with mild OAG. The outcome measures were quality-adjusted life-years (QALYs) gained, cost from the societal perspective, and the incremental cost-effectiveness ratio (ICER) of medication, laser trabeculoplasty, and trabeculectomy. Interventions were evaluated at a willingness-to-pay (WTP) threshold of 30,000,000 KRW ($29,152) per QALY gained. Deterministic and probabilistic sensitivity analyses were conducted to address the model uncertainty. RESULTS: The mean costs for medication, laser trabeculoplasty, and trabeculectomy were 29,661,740 KRW, 17,34,1342 KRW, and 22,275,438 KRW, respectively. The mean QALYs gained were 15.7, 15.3, and 14.8 for medication, laser trabeculoplasty, and trabeculectomy, respectively. Surgery was strongly dominated because it generated fewer expected QALYs but incurred greater expected cost than laser. The ICER was 30,885,179 KRW per QALY for medication versus laser trabeculoplasty. Laser was cost-effective, however, at a lower WTP threshold of 21,000,000 KRW per QALY gained or below. The results were most sensitive to the progression rates from mild to moderate glaucoma under laser treatment. CONCLUSION: Under the WTP threshold of 30,000,000 KRW per QALY, medication was cost-effective compared with laser trabeculoplasty and trabeculectomy for treating mild OAG in South Korean population. Laser, however, can be a cost-effective alternative in more resource-limited settings.
format Online
Article
Text
id pubmed-6336655
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-63366552019-01-24 The cost-effectiveness of medication, laser trabeculoplasty, and trabeculectomy for treatment of open-angle glaucoma in South Korea Choi, Jin A. Song, Lina D. Choi, Seulggie Park, Sang Min Kwon, Jin Woo Jee, Donghyun Medicine (Baltimore) Research Article OBJECTIVES: Open-angle glaucoma (OAG) imposes high disease burden in South Korea. Although various effective interventions are available to manage the progression of OAG, there is limited data on the cost-effectiveness of these treatment strategies in South Korea. METHODS: Using a Markov cohort model, we evaluated the cost-effectiveness of 3 major treatment strategies (medication, laser trabeculoplasty, and trabeculectomy) for South Korean patients with OAG. We projected a 25-year time horizon to study a hypothetical cohort of 10,000 patients of age 40 with mild OAG. The outcome measures were quality-adjusted life-years (QALYs) gained, cost from the societal perspective, and the incremental cost-effectiveness ratio (ICER) of medication, laser trabeculoplasty, and trabeculectomy. Interventions were evaluated at a willingness-to-pay (WTP) threshold of 30,000,000 KRW ($29,152) per QALY gained. Deterministic and probabilistic sensitivity analyses were conducted to address the model uncertainty. RESULTS: The mean costs for medication, laser trabeculoplasty, and trabeculectomy were 29,661,740 KRW, 17,34,1342 KRW, and 22,275,438 KRW, respectively. The mean QALYs gained were 15.7, 15.3, and 14.8 for medication, laser trabeculoplasty, and trabeculectomy, respectively. Surgery was strongly dominated because it generated fewer expected QALYs but incurred greater expected cost than laser. The ICER was 30,885,179 KRW per QALY for medication versus laser trabeculoplasty. Laser was cost-effective, however, at a lower WTP threshold of 21,000,000 KRW per QALY gained or below. The results were most sensitive to the progression rates from mild to moderate glaucoma under laser treatment. CONCLUSION: Under the WTP threshold of 30,000,000 KRW per QALY, medication was cost-effective compared with laser trabeculoplasty and trabeculectomy for treating mild OAG in South Korean population. Laser, however, can be a cost-effective alternative in more resource-limited settings. Wolters Kluwer Health 2019-01-11 /pmc/articles/PMC6336655/ /pubmed/30633194 http://dx.doi.org/10.1097/MD.0000000000014026 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Research Article
Choi, Jin A.
Song, Lina D.
Choi, Seulggie
Park, Sang Min
Kwon, Jin Woo
Jee, Donghyun
The cost-effectiveness of medication, laser trabeculoplasty, and trabeculectomy for treatment of open-angle glaucoma in South Korea
title The cost-effectiveness of medication, laser trabeculoplasty, and trabeculectomy for treatment of open-angle glaucoma in South Korea
title_full The cost-effectiveness of medication, laser trabeculoplasty, and trabeculectomy for treatment of open-angle glaucoma in South Korea
title_fullStr The cost-effectiveness of medication, laser trabeculoplasty, and trabeculectomy for treatment of open-angle glaucoma in South Korea
title_full_unstemmed The cost-effectiveness of medication, laser trabeculoplasty, and trabeculectomy for treatment of open-angle glaucoma in South Korea
title_short The cost-effectiveness of medication, laser trabeculoplasty, and trabeculectomy for treatment of open-angle glaucoma in South Korea
title_sort cost-effectiveness of medication, laser trabeculoplasty, and trabeculectomy for treatment of open-angle glaucoma in south korea
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336655/
https://www.ncbi.nlm.nih.gov/pubmed/30633194
http://dx.doi.org/10.1097/MD.0000000000014026
work_keys_str_mv AT choijina thecosteffectivenessofmedicationlasertrabeculoplastyandtrabeculectomyfortreatmentofopenangleglaucomainsouthkorea
AT songlinad thecosteffectivenessofmedicationlasertrabeculoplastyandtrabeculectomyfortreatmentofopenangleglaucomainsouthkorea
AT choiseulggie thecosteffectivenessofmedicationlasertrabeculoplastyandtrabeculectomyfortreatmentofopenangleglaucomainsouthkorea
AT parksangmin thecosteffectivenessofmedicationlasertrabeculoplastyandtrabeculectomyfortreatmentofopenangleglaucomainsouthkorea
AT kwonjinwoo thecosteffectivenessofmedicationlasertrabeculoplastyandtrabeculectomyfortreatmentofopenangleglaucomainsouthkorea
AT jeedonghyun thecosteffectivenessofmedicationlasertrabeculoplastyandtrabeculectomyfortreatmentofopenangleglaucomainsouthkorea
AT choijina costeffectivenessofmedicationlasertrabeculoplastyandtrabeculectomyfortreatmentofopenangleglaucomainsouthkorea
AT songlinad costeffectivenessofmedicationlasertrabeculoplastyandtrabeculectomyfortreatmentofopenangleglaucomainsouthkorea
AT choiseulggie costeffectivenessofmedicationlasertrabeculoplastyandtrabeculectomyfortreatmentofopenangleglaucomainsouthkorea
AT parksangmin costeffectivenessofmedicationlasertrabeculoplastyandtrabeculectomyfortreatmentofopenangleglaucomainsouthkorea
AT kwonjinwoo costeffectivenessofmedicationlasertrabeculoplastyandtrabeculectomyfortreatmentofopenangleglaucomainsouthkorea
AT jeedonghyun costeffectivenessofmedicationlasertrabeculoplastyandtrabeculectomyfortreatmentofopenangleglaucomainsouthkorea